Astressin 2B

Product Name:Astressin 2B

CAS No:681260-70-8

Purity:95%

Molar Mass:4041.69

Chemical Formula:C183H307N49O53

Storage:Store at -20 degrees Celsius

Sequence:DLSFHLLRKXIEIEKQEKEKQQAENNKLLLDLI

Target:corticotropin-releasing factor receptor 2 (CRF2) antagonist

Application:

Astressin 2B is a potent and selective antagonist of the corticotropin-releasing factor (CRF) receptor 2. This peptide is essential for research into stress-related disorders, as it blocks CRF receptor 2, which is implicated in the regulation of stress, anxiety, and cardiovascular function. Astressin 2B is particularly useful in studies exploring the role of CRF signaling in the hypothalamic-pituitary-adrenal (HPA) axis and its impact on stress-related pathologies. With its high specificity, purity, and stability, Astressin 2B ensures reliable results, making it a valuable tool for neuroendocrine and behavioral research.

Current Research:

Astressin 2B is a potent and selective antagonist of corticotropin-releasing factor receptor 2 (CRF2), a receptor subtype intricately involved in stress-related physiological processes and homeostatic regulation. CRF2 is implicated in the modulation of cardiovascular function, energy balance, and behavioral responses to stress, positioning Astressin 2B as a crucial tool in delineating the receptor's specific roles. Recent studies underscore the therapeutic potential of targeting CRF2 in neuropsychiatric disorders, including anxiety and depression. Astressin 2B has been pivotal in preclinical investigations, revealing the nuanced interplay between CRF2 signaling and the hypothalamic-pituitary-adrenal (HPA) axis. Its ability to selectively inhibit CRF2 without affecting CRF1 has enabled researchers to parse out receptor-specific pathways, offering insights into their discrete contributions to pathophysiology. Moreover, Astressin 2B has gained attention for its role in cardiovascular research. By modulating CRF2-mediated vasodilatory and cardioprotective mechanisms, this compound has shed light on potential therapeutic strategies for conditions such as heart failure and hypertension. Studies indicate that CRF2 antagonism may influence endothelial function and myocardial stress responses, paving the way for novel interventions. Astressin 2B's applications extend to metabolic research, where its effects on energy expenditure and feeding behavior are under scrutiny. Preclinical models suggest that CRF2 inhibition may alter metabolic homeostasis, particularly under stress-induced conditions, highlighting a potential avenue for addressing obesity and metabolic syndrome. As a highly selective CRF2 antagonist, Astressin 2B remains indispensable in translational research aimed at therapeutic innovation. By enabling the precise characterization of CRF2-related pathways, it continues to drive advancements in pharmacological science, with promising implications for the treatment of stress-associated and metabolic disorders.

Reference:

Rivier, J. E., & Rivier, C. L. (2014). Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance. Frontiers in neuroendocrinology, 35(2), 161-170.